Nabota, the botulinum toxin from Daewoong Pharmaceutical (069620.KS) that has surpassed 1 trillion won ($720 million) in cumulative sales, is stepping up its push into global markets. The company said it plans to expand beyond the 69 countries where the product is approved by strengthening the local sales and marketing capabilities of its overseas partners.
Daewoong Pharmaceutical said on the 7th that it held the NABOTA® EDGE: Global Academic Program from the 3rd through the 5th at the Parnas Hotel Jeju for 40 key staff from partner companies in 22 countries.
Nabota passed 1 trillion won in cumulative sales this year and is expected to reach 300 billion won in annual sales. It has won product approvals in 69 countries across the United States, Europe and Asia, and has built partnerships in about 80 countries.
The program was designed to sharpen the ability of partner companies to execute in their own markets as Nabota's global business expands. Sessions covered market entry and brand strategy by country, product characteristics, standard injection guidelines and responses to competing products. Partners also shared local marketing success stories and business know-how.
Daewoong Pharmaceutical said it plans to expand training and networking programs for global partners and to run tailored advanced programs based on years of experience.
"Key staff from Nabota partners around the world shared an understanding of the product and business strategy, and we have laid the groundwork for stronger execution in local markets," said Yoon Jun-soo, head of the Nabota business division at Daewoong Pharmaceutical. "We will continue to strengthen the capabilities of our global partners and our collaboration with them."
